Recently, there has been a long lost rebound in the pharmaceutical and biological sectors. Despite the previous "continuous decline", the attention of institutions to pharmaceutical, electronic and other sectors has not decreased.
According to the data, as of February 15, 636 A-share listed companies have been investigated by securities companies since 2022. In terms of industry, there are many companies in electronics, medicine and other industries.
In the view of institutions, this round of rebound is expected to continue. It is suggested to pay attention to investment opportunities in digital economy, new energy, medicine, military industry and other fields.
the more you fall, the more you pay attention to
the two industries have been intensively investigated by securities companies
According to the data, as of February 15, 636 A-share listed companies have been investigated by securities companies since 2022, of which Huadong Medicine Co.Ltd(000963) has attracted the most attention, and 67 securities companies have been investigated during the year. In the survey, the company's product R & D and clinical progress, sales promotion, medical and American business layout and how to view the future industrial development trend were asked more.
From the stock price trend, as an enterprise dominated by the pharmaceutical industry and expanding the pharmaceutical business and medical beauty industry at the same time, Huadong Medicine Co.Ltd(000963) the stock price rose 4.71% on February 15, but its cumulative decline during the year still reached 6.07%.
Since reaching a new high on July 1, 2021, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) share price has continued to decline. As of the closing on February 15, it has fallen by more than 16% since 2022. However, the company has received 59 securities companies to conduct research this year, ranking fourth among 636 companies. From the survey minutes, the company's share price repurchase, the basis for formulating the assessment objectives of the employee stock ownership plan, the development opportunities of the pet medical device market and other topics were asked by securities companies.
It is found that Andon Health Co.Ltd(002432) , Shanghai Medicilon Inc(688202) , Qingdao Novelbeam Technology Co.Ltd(688677) , Aohua endoscopy and other pharmaceutical and biological companies ranked among the top in the number of securities companies surveyed during the year. On the whole, of the 636 listed companies surveyed by securities companies this year, 83 belong to the pharmaceutical and biological industry, only one less than the electronics industry ranking first.
From 2022 to now, it has received research from securities companies and the top ten listed companies
Similar to the pharmaceutical and biological industry, since mid December 2021, the electronic sector as a whole has shown a high decline trend. Many electronic industry companies receiving intensive research from securities companies also continue to have their share prices in a callback state. For example Yangzhou Yangjie Electronic Technology Co.Ltd(300373) , as of February 15, the company has received a total of 29 securities companies since 2022. Since November 24, 2021, when the share price reached a new high for listing, it has continued to fluctuate and fall.
From the perspective of other industries, since this year, there have been more listed companies investigated by securities companies, including 79 and 67 in mechanical equipment and computer industries respectively. In contrast, since the beginning of the year, securities companies have conducted less research on companies in petroleum and petrochemical, coal, non bank finance and other sectors.
layout growth style is at the right time
Since this year, undervalued blue chips have led the rise, while the growth style of science and technology has been significantly suppressed. Recently, however, the value of the sector has rebounded further, and many institutions have also been optimistic about the growth of the market.
In Huaan Securities Co.Ltd(600909) view, the recent growth style has remained sluggish, mainly because the Fed's expectation of raising interest rates has been strengthened, which has restrained the risk appetite of US stocks and mapped to the growth style of a shares; In addition, factors such as relatively high valuation and falling growth expectations have also exacerbated the suppression of risk appetite for growth style. However, with the weakening of these inhibitory factors and the time and space for this round of adjustment of growth style basically in place, the growth style is expected to deduce a new round of market with the support of the continuation of high prosperity, loose liquidity and policy support for the development of new energy vehicles and semiconductor industry. The current layout is at the right time.
For whether the pharmaceutical and biological industry has been callback to the time worthy of layout, Capital Securities believes that the fundamentals of the pharmaceutical and biological industry have not changed significantly. Based on the judgment of fundamentals and valuation level, the period of overall sharp decline in the pharmaceutical industry has basically ended, but it does not rule out that some industries such as CXO industry may still be affected by overseas factors and continue to be weak in the short term. Among the subdivided industries, the sectors of biological products, research and experimental development and rehabilitation equipment are promising.
As far as the electronics industry is concerned, the semiconductor field is more favored by institutions. Guosheng securities judged that the sustainability of this round of global semiconductor boom is expected to further exceed expectations by combing the relevant data of global semiconductor companies that have released the financial report for the fourth quarter of 2021. The global leading orders for core equipment are strong as a whole, and the short-term income is limited by the supply chain. Guosheng securities stressed that the pattern of China's semiconductor industry will usher in an unprecedented reconstruction, and the leaders of consumer electronics segments, including semiconductor core design and apple industry chain core leading companies, deserve attention.
For the recent market rebound, Founder Securities Co.Ltd(601901) believes that the oversold is the biggest driving force of the rebound. This round of rebound is expected to continue, optimistic about the performance of small cap stocks in science and technology growth in emerging industries. Soochow Securities Co.Ltd(601555) believes that the market balance is expected to tilt towards growth. It is suggested to pay attention to the rebound opportunities of digital economy, new energy, medicine and military industry.
